Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 13/20 | 0.51 |
| ▸ | ELOVL3 | Q9HB03 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738589 | 0.87 | ELOVL6 (0.50) | ELOVL6MMP13PPARGPPARAAAK1 | |
| SCHEMBL3742829 | 0.83 | ELOVL6 (0.46) | ELOVL6MAPTMMP13PPARGPPARA | |
| SCHEMBL3747169 | 0.78 | ELOVL6 (0.56) | ELOVL6ELOVL3 | |
| SCHEMBL3751575 | 0.77 | MMP13 (0.41) | ELOVL6MMP13AAK1 | |
| SCHEMBL3744310 | 0.77 | CHRM2 (0.55) | MMP13AAK1 | |
| SCHEMBL3742008 | 0.75 | CTSS (0.42) | MAPTMMP13AAK1 | |
| SCHEMBL3736645 | 0.75 | ELOVL6 (0.43) | ELOVL6MAPTMMP13PPARGPPARA | |
| SCHEMBL3741700 | 0.74 | AAK1 (0.40) | MMP13AAK1 | |
| SCHEMBL3741039 | 0.74 | CMA1 (0.44) | ELOVL6PPARGPPARA | |
| SCHEMBL3747163 | 0.74 | AAK1 (0.41) | MMP13AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | claimed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | claimed |
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009037719-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | ELOVL6 1589/4885ELOVL3 1620/4885MAPT 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.